Optimi Health Corp. (CSE: OPTI)
OPTI trades on the Canadian Securities Exchange in Life Sciences, headquartered in British Columbia. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of November 13, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for OPTI.CN, last bar 2026-11-13, computed by MarginsX.
Profile
| Field | Value |
|---|---|
| Ticker | OPTI on the Canadian Securities Exchange |
| Yahoo symbol | OPTI.CN |
| Sector | Life Sciences, Drug Manufacturers—Specialty & Generic |
| Headquarters | British Columbia |
| Listed | The TMX list gives no listing date |
| Listing type | TMX leaves listing type blank for long-listed issuers |
| Shares outstanding | Not on the TMX list |
| Also listed on | No interlisting on the TMX list |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0002027329 |
| Website | No company website on record |
| US listing | OPTH |
Returns
| Window | Return |
|---|---|
| 1 day | +1.9% |
| 1 week | -2.1% |
| 1 month | -36.0% |
| 3 months | -52.2% |
| 6 months | -65.6% |
| Year to date | -66.1% |
| 1 year | -70.8% |
| From 52-week high | -72.6% |
| 52-week range | C$2.95 to C$11.70 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
94 documents in 8 types. Each title links to the document at its source.
Interim financial statements (2)
| Document | Type | Filed |
|---|---|---|
| Condensed interim consolidated financial statements for the period ended June 30, 2026 Period 2026-06-30 | Interim financial statements (6-K) | 2026-08-14 |
| Condensed interim consolidated financial statements for the period ended March 31, 2026 Period 2026-03-31 | Interim financial statements (6-K) | 2026-06-02 |
MD&A (2)
| Document | Type | Filed |
|---|---|---|
| Management's Discussion and Analysis for the period ended June 30, 2026 Period 2026-06-30 | MD&A (interim) (6-K) | 2026-08-14 |
| Management’s Discussion and Analysis for the period ended March 31, 2026 Period 2026-03-31 | MD&A (interim) (6-K) | 2026-06-02 |
Material change report (1)
| Document | Type | Filed |
|---|---|---|
| Material Change Report | Material change report (6-K) | 2026-08-27 |
News release (17)
| Document | Type | Filed |
|---|---|---|
| PRESS RELEASE | News release (6-K) | 2026-10-26 |
| PRESS RELEASE | News release (6-K) | 2026-10-20 |
| PRESS RELEASE | News release (6-K) | 2026-10-07 |
| PRESS RELEASE | News release (6-K) | 2026-09-29 |
Management information circular / proxy (3)
| Document | Type | Filed |
|---|---|---|
| NOTICE AND INFORMATION CIRCULAR | Management information circular (6-K) | 2026-07-28 |
| FORM OF PROXY | Form of proxy / voting instruction (6-K) | 2026-07-28 |
| VOTING INSTRUCTION FORM | Form of proxy / voting instruction (6-K) | 2026-07-28 |
Prospectus (11)
| Document | Type | Filed |
|---|---|---|
| 424B4 | Prospectus supplement (424B4) | 2026-05-20 |
| REGISTRATION STATEMENT | Prospectus (long form) (F-1) | 2026-08-17 |
| F-1/A | Prospectus (long form) (F-1/A) | 2026-05-19 |
| F-1/A | Prospectus (long form) (F-1/A) | 2026-04-23 |
Early warning / ownership (3)
| Document | Type | Filed |
|---|---|---|
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-10-05 |
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2026-08-07 |
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2026-05-27 |
Other (55)
| Document | Type | Filed |
|---|---|---|
| OPINION OF NORTON ROSE FULBRIGHT CANADA LLP REGARDING THE VALIDITY OF THE COMMON | Consent (F-1) | 2026-08-17 |
| CONSENT OF DAVIDSON & COMPANY LLP, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING F | Consent (F-1) | 2026-08-17 |
| EX-5.2 | Consent (F-1/A) | 2026-05-19 |
| EX-23.1 | Consent (F-1/A) | 2026-05-19 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
No CIRO halt notices for this company in our data.
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Recent
| Date | Time | Event | Webcast | Source |
|---|---|---|---|---|
| 2026-10-15 | No time in the announcement | ThinkEquity Conference Conference presentation | No webcast link announced | SEC filing |
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2024-08-26 | Equity, Option To Acquire, Security To Be Acquired | US$194K | US$321K | SEC EDGAR |
| 2024-06-26 | Equity, Option To Acquire, Security To Be Acquired | US$191K | US$317K | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| NAV | NAVCO Pharmaceuticals Inc. | TSXV | C$285K | 0.0% | 0.0% |
| EVMT | Evome Medical Technologies Inc. | TSXV | C$301K | 0.0% | 0.0% |
| ARC | ARCpoint Inc. | TSXV | C$332K | 0.0% | 0.0% |
| VXL | Vaxil Bio Ltd. | TSXV | C$398K | -24.1% | -35.3% |
| WAVE | Waverley Pharma Inc. | TSXV | C$540K | +100.0% | 0.0% |
The app has the price chart, every filing, private raises and the full peer set for OPTI.
Open in the app